Clinical Trials Browser

Breast Neoplasms × sapanisertib × Clear all

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase 2 Completed

118 enrolled 30 charts

Breast Neoplasms

NCT02756364 2023-02-08

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Phase 2 Completed

141 enrolled 18 charts

Breast Neoplasms

NCT02988986 2021-09-22

ANETT

Phase 2 Completed

28 enrolled 9 charts

Breast Neoplasms

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms